mechanism of action of glp 1 agonist GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Incretin-based therapy of metabolic disease
Description
They were randomly assigned in a 2:1 ratio, to 68 weeks of treatment with semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention
2024 [updated December 4, 2024
[DOI] [PubMed] [Google Scholar] 52.Exton J.H., Park C.R
Statements Author contributions DA: Resources, Funding acquisition, Formal analysis, Software, Conceptualization, Methodology, Writing original draft, Investigation, Data curation
The native amylin hormone lasts only minutes in circulation
